KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Current Assets (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Current Assets for 18 consecutive years, with $2.9 billion as the latest value for Q1 2026.

  • For Q1 2026, Current Assets rose 21.41% year-over-year to $2.9 billion; the TTM value through Mar 2026 reached $2.9 billion, up 21.41%, while the annual FY2025 figure was $3.0 billion, 14.13% up from the prior year.
  • Current Assets hit $2.9 billion in Q1 2026 for Ionis Pharmaceuticals, down from $3.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $3.0 billion in Q4 2025 and bottomed at $2.2 billion in Q3 2022.
  • Average Current Assets over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2023.
  • Year-over-year, Current Assets fell 10.98% in 2024 and then rose 21.41% in 2026.
  • Ionis Pharmaceuticals' Current Assets stood at $2.2 billion in 2022, then grew by 19.94% to $2.6 billion in 2023, then dropped by 0.82% to $2.6 billion in 2024, then rose by 14.13% to $3.0 billion in 2025, then fell by 1.8% to $2.9 billion in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $2.9 billion, $3.0 billion, and $2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.